Document is current
Any future updates will be listed below
-
Authors
Henriet, Elodie
Knutsdottir, Hildur
Grasset, Eloise M.
Dunworth, Matthew
Haynes, Meagan
Bader, Joel S.
Ewald, Andrew J. https://orcid.org/0000-0002-1964-0740
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA268083, U54CA268083, 3P30CA006973)
Breast Cancer Research Foundation (BCRF-21-048)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U01CA217846)
- License Information
-
More Information
Article History
Received: 10 June 2022
Revised: 13 December 2022
Accepted: 19 December 2022
First Online: 5 January 2023
Competing interests
: AJE has unlicensed patents and patent applications related to the use of K14 as a prognostic biomarker, to the use of antibodies in cancer treatment, and to 3D culture protocols for tumor organoids. AJE’s spouse is an employee of Immunocore. JSB is a founder of Neochromosome and consultant for its parent company Opentrons Labworks Inc and serves on the SAB of Reflexion Pharmaceuticals. The other authors declare no competing interests.
